In a patient who developed angioedema from lisinopril, can they safely be treated with valsartan, other angiotensin‑II receptor blockers (ARBs), or sacubitril/valsartan (Entresto)?

ARB and Entresto Use After ACE Inhibitor-Induced Angioedema

Direct Answer

ARBs (including valsartan) can be used cautiously in patients with prior ACE inhibitor-induced angioedema, but Entresto (sacubitril/valsartan) is contraindicated in this population.

---

ARB Use After ACE Inhibitor Angioedema

Safety Profile and Cross-Reactivity Risk

• Patients who develop angioedema from ACE inhibitors should be started on an ARB as an alternative, though caution is required because some patients have also developed angioedema with ARBs 1.

• The cross-reactivity rate is approximately 10% or less when switching from an ACE inhibitor to an ARB after angioedema 2.

• ARBs do not inhibit kininase (unlike ACE inhibitors), which accounts for their much lower incidence of both cough and angioedema 1.

• ARB-associated angioedema tends to be less severe and occurs earlier in treatment compared to ACE inhibitor-induced angioedema 2.

Clinical Implementation

• ARBs should be reserved for patients with high therapeutic need for renin-angiotensin system inhibition 2.

• Treatment should be initiated with close observation, and patients must be educated on the signs of angioedema with emphasis on proper emergency management 2.

• The FDA label for valsartan explicitly states that valsartan should not be re-administered to patients who have had angioedema, and notes that some patients who experienced angioedema had previously experienced it with other drugs, including ACE inhibitors 3.

• Switching directly to an ARB without careful patient counseling is not recommended, as a modest risk of recurrent angioedema exists, though most patients eventually tolerate ARBs 4.

---

Entresto (Sacubitril/Valsartan) is Contraindicated

Absolute Contraindication

• Entresto is contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 5.

• The FDA label explicitly states: "ENTRESTO must not be used in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy" 5.

• If angioedema occurs with Entresto, the drug must be discontinued immediately and must not be re-administered 5.

Mechanistic Rationale

• The combination of neprilysin inhibition with ACE inhibition leads to unacceptable angioedema rates, as demonstrated by the terminated development of omapatrilat (a combined neprilysin/ACE inhibitor) 1.

• Both ACE inhibitors and neprilysin break down bradykinin, and their combined inhibition can directly or indirectly cause angioedema 1.

• Even when switching from an ACE inhibitor to Entresto, a 36-hour washout period is mandatory to minimize overlapping ACE and neprilysin inhibition 1, 5.

Real-World Evidence

• In the PARADIGM-HF trial, which excluded patients with prior ACE inhibitor-induced angioedema, confirmed angioedema occurred in 0.45% of sacubitril/valsartan patients versus 0.24% of enalapril patients during the double-blind phase 6.

• Recent real-world data show increased angioedema risk among patients who switched from ACE inhibitors or ARBs to sacubitril/valsartan, particularly when the switch occurred within 14 days (HR: 1.98 for recent ACE inhibitor switchers; HR: 2.45 for recent ARB switchers) 7.

---

Clinical Algorithm

For Your Patient with Lisinopril-Induced Angioedema:

1. Immediately discontinue lisinopril (already done) 4.

2. Entresto is absolutely contraindicated and should never be initiated 5.

3. If renin-angiotensin system blockade is essential (e.g., heart failure with reduced ejection fraction, post-MI):

   • Consider an ARB (e.g., valsartan, losartan) with extensive patient counseling 1, 2.
   • Start with close observation in a monitored setting 2.
   • Educate the patient on angioedema signs and emergency management 2.
   • Accept the ~10% cross-reactivity risk 2.

4. If renin-angiotensin system blockade is not absolutely essential, consider alternative antihypertensive classes entirely.

---

Critical Pitfalls to Avoid

• Do not assume ARBs are completely safe after ACE inhibitor angioedema—cross-reactivity occurs in up to 10% of patients 2.

• Never initiate Entresto in a patient with prior ACE inhibitor or ARB angioedema—this is an FDA black-box contraindication 5.

• Angioedema from ACE inhibitors may persist for up to 6 weeks after drug cessation, so do not prematurely attribute new swelling to a different cause 4.

• Black patients have higher rates of angioedema with both ACE inhibitors and Entresto, requiring extra vigilance 5.